$OPRX
OptimizeRx Corp Stock $oprx

$oprx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024098319 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024 Q2
Revenue		$21.31M	$18.81M
YoY Change		30.48%	36.14%
Cost Of Revenue		$7.862M	$7.108M
YoY Change		20.38%	18.6%
Gross Profit		$13.45M	$11.70M
YoY Change		37.21%	49.57%
Gross Profit Margin		63.1%	62.22%
Selling, General & Admin		$13.43M	$14.38M
YoY Change		4.17%	17.46%
% of Gross Profit		99.84%	122.86%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$1.095M	$1.073M
YoY Change		132.98%	130.87%
% of Gross Profit		8.14%	9.17%
Operating Expenses		$22.01M	$15.45M
YoY Change		64.81%	21.61%
Operating Profit		-$8.562M	-$3.749M
YoY Change		140.95%	-23.21%
Interest Expense		-$1.417M	-$1.422M
YoY Change		-305.36%	-297.38%
% of Operating Profit
Other Income/Expense, Net		-$1.379M	-$1.347M
YoY Change		-300.38%	-286.97%
Pretax Income		-$9.941M	-$5.096M
YoY Change		246.94%	22.46%
Income Tax		-$817.0K	-$1.088M
% Of Pretax Income
Net Earnings		-$9.124M	-$4.008M
YoY Change		218.43%	-3.69%
Net Earnings / Revenue		-42.82%	-21.31%
Basic Earnings Per Share		-$0.50	-$0.22
Diluted Earnings Per Share		-$0.50	-$0.22
COMMON SHARES
Basic Shares Outstanding	18.42M shares	18.32M shares	18.18M shares
Diluted Shares Outstanding		18.32M shares	18.26M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.13M	$14.96M
YoY Change	-74.6%	-76.16%
Cash & Equivalents	$16.13M	$14.96M
Short-Term Investments
Other Short-Term Assets	$4.389M	$4.647M
YoY Change	46.3%	14.66%
Inventory
Prepaid Expenses
Receivables	$26.33M	$24.52M
Other Receivables	$64.00K	$1.842M
Total Short-Term Assets	$46.91M	$45.97M
YoY Change	-46.33%	-45.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$161.0K	$171.0K
YoY Change	7.83%	21.3%
Goodwill	$70.90M	$78.36M
YoY Change	212.7%	245.58%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$362.0K	$434.0K
YoY Change	-67.09%
Total Long-Term Assets	$118.3M	$126.9M
YoY Change	223.74%	250.08%
TOTAL ASSETS
Total Short-Term Assets	$46.91M	$45.97M
Total Long-Term Assets	$118.3M	$126.9M
Total Assets	$165.2M	$172.9M
YoY Change	33.3%	42.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.754M	$2.980M
YoY Change	293.43%	264.4%
Accrued Expenses	$5.557M	$5.310M
YoY Change	78.74%	253.18%
Deferred Revenue	$786.0K	$1.054M
YoY Change	318.09%	133.7%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000M	$3.300M
YoY Change
Total Short-Term Liabilities	$14.50M	$14.96M
YoY Change	88.3%	171.45%
LONG-TERM LIABILITIES
Long-Term Debt	$33.28M	$32.30M
YoY Change
Other Long-Term Liabilities	$242.0K	$271.0K
YoY Change	142.0%
Total Long-Term Liabilities	$33.28M	$32.30M
YoY Change	33178.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.50M	$14.96M
Total Long-Term Liabilities	$33.28M	$32.30M
Total Liabilities	$50.73M	$51.86M
YoY Change	548.57%	841.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$84.29M	-$75.17M
YoY Change	40.21%	31.29%
Common Stock	$20.00K	$20.00K
YoY Change	8.77%	8.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.000K	$2.000K
YoY Change	14.88%	14.88%
Treasury Stock Shares
Shareholders Equity	$114.5M	$121.0M
YoY Change
Total Liabilities & Shareholders Equity	$165.2M	$172.9M
YoY Change	33.3%	42.49%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$9.124M	-$4.008M
YoY Change	218.43%	-3.69%
Depreciation, Depletion And Amortization	$1.095M	$1.073M
YoY Change	132.98%	130.87%
Cash From Operating Activities	$1.791M	$782.0K
YoY Change	21.84%	-133.02%
INVESTING ACTIVITIES
Capital Expenditures	$92.00K	$85.00K
YoY Change	-71.25%	-92.3%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$92.00K	-$85.00K
YoY Change	-90.89%	-102.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-532.0K	-915.0K
YoY Change	52.0%	-87.78%
NET CHANGE
Cash From Operating Activities	1.791M	782.0K
Cash From Investing Activities	-92.00K	-85.00K
Cash From Financing Activities	-532.0K	-915.0K
Net Change In Cash	1.167M	-218.0K
YoY Change	960.91%	-96.71%
FREE CASH FLOW
Cash From Operating Activities	$1.791M	$782.0K
Capital Expenditures	$92.00K	$85.00K
Free Cash Flow	$1.699M	$697.0K
YoY Change	47.74%	-120.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38543
	dei	Entity Registrant Name EntityRegistrantName	OptimizeRx Corporation
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1265381
	dei	Entity Address Address Line1 EntityAddressAddressLine1	260 Charles Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02453
	dei	City Area Code CityAreaCode	248
	dei	Local Phone Number LocalPhoneNumber	651-6568
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	OPRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18420906	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16126000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13852000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	339000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	239000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26327000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36253000	usd
CY2024Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	64000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1036000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4389000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3190000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	46906000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	54331000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	161000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	70869000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	78357000	usd
CY2024Q3	oprx	Technology Assets Net TechnologyAssetsNet	8383000	usd
CY2023Q4	oprx	Technology Assets Net TechnologyAssetsNet	9013000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5685000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6185000	usd
CY2024Q3	oprx	Tradename And Customer Relationships Net TradenameAndCustomerRelationshipsNet	32411000	usd
CY2023Q4	oprx	Tradename And Customer Relationships Net TradenameAndCustomerRelationshipsNet	34198000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	422000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	573000	usd
CY2024Q3	us-gaap	Security Deposit SecurityDeposit	362000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	568000	usd
CY2024Q3	oprx	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	118132000	usd
CY2023Q4	oprx	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	128894000	usd
CY2024Q3	us-gaap	Assets Assets	165199000	usd
CY2023Q4	us-gaap	Assets Assets	183374000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	usd
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2754000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2227000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5557000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7755000	usd
CY2024Q3	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	3210000	usd
CY2023Q4	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	5506000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	195000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	222000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	786000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	172000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14502000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17882000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33278000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34231000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	242000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	371000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2712000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4337000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	50734000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	56821000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20069432	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19899679	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2024Q3	oprx	Treasury Stock Par Value TreasuryStockParValue	0.001
CY2023Q4	oprx	Treasury Stock Par Value TreasuryStockParValue	0.001
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1741397	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1741397	shares
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198737000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	190793000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84290000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64258000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	114465000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	126553000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165199000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	183374000	usd
CY2024Q3	us-gaap	Revenues Revenues	21309000	usd
CY2023Q3	us-gaap	Revenues Revenues	16331000	usd
	us-gaap	Revenues Revenues	59811000	usd
	us-gaap	Revenues Revenues	43153000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	7862000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	6531000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	22456000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	18094000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	13447000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	9800000	usd
	us-gaap	Gross Profit GrossProfit	37355000	usd
	us-gaap	Gross Profit GrossProfit	25059000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13425000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12886000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43971000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39162000	usd
CY2024Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7489000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7489000	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1095000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	467000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3235000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1395000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	22009000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	13353000	usd
	us-gaap	Operating Expenses OperatingExpenses	54695000	usd
	us-gaap	Operating Expenses OperatingExpenses	40557000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8562000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3553000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17340000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15499000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1524000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4597000	usd
CY2024Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	38000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	113000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	107000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	688000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	231000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2074000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1379000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	688000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4253000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2074000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9941000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2865000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21593000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13424000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-817000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1561000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-9124000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2865000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20032000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13424000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18323542	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16637606	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18250775	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16907482	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18323542	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16637606	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18250775	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16907482	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.5
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.1
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.5
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.1
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	126553000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1353000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1671000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-140000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6900000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	122537000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1149000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1753000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-415000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-4008000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	121016000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	992000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1612000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-31000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-9124000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	114465000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126111000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1467000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	2914000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-170000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6398000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	123964000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1655000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1848000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	105000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-73000	usd
CY2023Q2	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	7522000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4161000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	115815000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1598000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	1608000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-49000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2865000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	116107000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20032000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13424000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3235000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1395000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8530000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11090000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7489000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1625000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	131000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	478000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	547000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9795000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-838000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1200000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	728000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	527000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-859000	usd
	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-2296000	usd
	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-305000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1997000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	509000	usd
	oprx	Increase Decrease In Tax Receivable IncreaseDecreaseInTaxReceivable	972000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	615000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	24000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4691000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-982000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	95000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	162778000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	165089000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	235000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	1561000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-330000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	664000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	587000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	293000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	146000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7522000	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	300000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2087000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7969000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2274000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8287000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13852000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18209000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16126000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9923000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4081000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	158000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The accompanying condensed consolidated financial statements include OptimizeRx Corporation and its wholly owned subsidiaries (collectively, the “Company”, “we”, “our”, or “us”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We are a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over two million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary point-of-care network, as well as mass digital communications channels, OptimizeRx helps life sciences organizations engage and support their customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The condensed consolidated financial statements for the three and nine months ended September 30, 2024 and 2023 have been prepared by us without audit pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments necessary to present fairly our financial position at September 30, 2024, and our results of operations, changes in stockholders’ equity, and cash flows for the nine months ended September 30, 2024 and 2023, have been made. Those adjustments consist of normal and recurring adjustments. The condensed consolidated balance sheet as of December 31, 2023, has been derived from the audited consolidated condensed balance sheet as of that date. We operate a single reporting segment and, accordingly, use our consolidated net income as our measure of profit and loss and it is not presented separately here.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Certain information and note disclosures, including a detailed discussion about the Company’s significant accounting policies, normally included in our annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with a reading of the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on April 15, 2024 (“Form 10-K”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the results to be expected for the full year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On October 24, 2023, the Company acquired 100% of the issued and outstanding preferred and common stock of Healthy Offers, Inc., a Nevada corporation d/b/a Medicx Health (“Medicx Health”) - See Part II, Item 8. Financials Statements and Supplementary Data; Note 3 - Acquisitions in our Form 10-K for additional information regarding this transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The following presents the pro forma consolidated statement of operations as if Medicx Health had been included in the consolidated results of the Company for the three and nine months ended September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months<br/> Ended</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months<br/> Ended</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Pro-forma consolidated statement of operations</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,852</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">67,291</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,484</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,141</td><td style="text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These amounts have been calculated after applying the Company’s accounting policies, adjusting Medicx Health results to reflect the additional amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied on January 1, 2023, interest expense associated with the term loan and elimination of interest income on short-term investments that were used to fund the acquisition,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended December 31, 2023, the Company disposed of its non-core Access business - See Part II, Item 8. Financials Statements and Supplementary Data; Note 7 - Goodwill and Intangible Assets in our Form 10-K for additional information regarding this transaction. A pro forma statement of operations for the three and nine months ended September 30, 2024 is not presented for this transaction as the pro forma impacts were not material to the Company’s consolidated results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenue presented in the pro forma financial consolidated statement of operations data above includes $1,088 and $4,169, respectively related to the Access and other non-core solutions for which no revenue was recorded in the three and nine months ended September 30, 2024 (see also the discussion under Net Revenues in Results of Operations for the three and nine months ended September 30, 2024 in Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Change in Accounting Estimate</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with its policy, the Company periodically reviews the stand-alone selling prices of its performance obligations under <i>Revenue from Contracts with Customers</i> (“ASC Topic 606”) for use in allocating the contract prices. As a result, effective April 1, 2024, the Company updated the methodology for determining the value of program design and consulting services from the residual method to using an adjusted market assessment approach. The effect of this change in estimate was immaterial to the results for the three and nine months ended September 30, 2024, but may become material in future periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Fair Value of Financial Instruments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using Level 3 inputs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company’s carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and other current liabilities, approximate their fair values due to their short maturities.</span></p>
	oprx	Number Of Us Providers NumberOfUSProviders	2000000	pure
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	23852000	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	67291000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-3484000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-18141000	usd
CY2024Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	8200000	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	0	usd
CY2024Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	91000	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	233000	usd
CY2023Q3	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	48000	usd
	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	143000	usd
CY2024Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	217000	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	696000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	70900000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	78400000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	7500000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	36790000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	38290000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	usd
CY2024Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1512000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2059000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33278000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34231000	usd
CY2024Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	182000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	547000	usd
	oprx	Leverage Ratio Description LeverageRatioDescription	In addition, the Company is required to make a mandatory prepayment on March 31, of each year, commencing with 2025, equivalent to Excess Cash Flow multiplied by a percentage factor of 25%, if the leverage ratio is 3.60 to 1.00 or less, 50% if the leverage ratio is greater than 3.60 to 1 or less than or equal; to 4.10 to 1.00 and 75%, if the leverage ratio is greater than 4.10 to 1.00.
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	500000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	32290000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	36790000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	62000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	11000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	186000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	61000	usd
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1000	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	19000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	27000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	63000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	30000	usd
	us-gaap	Lease Cost LeaseCost	188000	usd
	us-gaap	Lease Cost LeaseCost	88000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	67000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	188000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	114000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	67000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	46000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	482000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	45000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	437000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0696	pure
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	168000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	53000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	193000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	60000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	175000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	61000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	52092	shares
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	585571000	usd
CY2023Q1	srt	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	15000000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4450000	shares
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4115000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M25D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	8000	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	16000	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	16000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	591000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	541000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	23191000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2021000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	786000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	172000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	172000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	164000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-3228000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-2444000	usd
CY2024Q1	oprx	Contract With Customer Liability Amount Collected ContractWithCustomerLiabilityAmountCollected	3961000	usd
CY2023Q1	oprx	Contract With Customer Liability Amount Collected ContractWithCustomerLiabilityAmountCollected	3015000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	905000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	735000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1853000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-3171000	usd
CY2024Q2	oprx	Contract With Customer Liability Amount Collected ContractWithCustomerLiabilityAmountCollected	2002000	usd
CY2023Q2	oprx	Contract With Customer Liability Amount Collected ContractWithCustomerLiabilityAmountCollected	2887000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1054000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	451000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-2721000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-3043000	usd
CY2024Q3	oprx	Contract With Customer Liability Amount Collected ContractWithCustomerLiabilityAmountCollected	2453000	usd
CY2023Q3	oprx	Contract With Customer Liability Amount Collected ContractWithCustomerLiabilityAmountCollected	2780000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	786000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	188000	usd
CY2024Q3	us-gaap	Revenues Revenues	21309000	usd
CY2023Q3	us-gaap	Revenues Revenues	16331000	usd
	us-gaap	Revenues Revenues	59811000	usd
	us-gaap	Revenues Revenues	43153000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	239000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	352000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	132000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	128000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	371000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	480000	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	111000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	371000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	591000	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000	usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	239000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	31000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	9000	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	339000	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	821000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-9124000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2865000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20032000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13424000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18323542	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16637606	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18250775	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16907482	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18323542	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16637606	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18250775	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16907482	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.5
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.1
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.5
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.1
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	146924	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	41077	shares
CY2024Q3	us-gaap	Other Commitment OtherCommitment	16700000	usd
CY2024Q3	us-gaap	Other Commitments Future Minimum Payments Remainder Of Fiscal Year OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear	1800000	usd
CY2024Q3	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	8800000	usd
CY2024Q3	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	3600000	usd
CY2024Q3	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	2400000	usd
CY2024Q3	us-gaap	Other Commitment Due In Fourth Year OtherCommitmentDueInFourthYear	100000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-817000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1561000	usd
CY2024Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.082	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.072	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	16700000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q3	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	oprx	Increase Decrease In Tax Receivable IncreaseDecreaseInTaxReceivable		usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities		usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts		usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2024Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2024Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2023Q3	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit		usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001448431

Files In Submission

Name	View Source	Status
0001213900-24-098319-index-headers.html	Edgar Link	pending
0001213900-24-098319-index.html	Edgar Link	pending
0001213900-24-098319.txt	Edgar Link	pending
0001213900-24-098319-xbrl.zip	Edgar Link	pending
ea0220081-10q_optimizerx.htm	Edgar Link	pending
ea022008101ex31-1_optimizerx.htm	Edgar Link	pending
ea022008101ex31-2_optimizerx.htm	Edgar Link	pending
ea022008101ex32-1_optimizerx.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oprx-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
oprx-20240930_cal.xml	Edgar Link	unprocessable
oprx-20240930_lab.xml	Edgar Link	unprocessable
oprx-20240930_def.xml	Edgar Link	unprocessable
oprx-20240930_pre.xml	Edgar Link	unprocessable
ea0220081-10q_optimizerx_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPRX
OptimizeRx Corp Stock $oprx

2024 Q4 Form 10-Q Financial Statement

#000121390024098319 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX OptimizeRx Corp Stock $oprx

2024 Q4 Form 10-Q Financial Statement

#000121390024098319 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX
OptimizeRx Corp Stock $oprx